Sunday, October 18, 2026

The Estée Lauder Companies Announces BEAUTY&YOU India 2026 Winners and Marks Five Years of Advancing Indian Beauty Entrepreneurship

 In partnership with Startup India and Nykaa, the program recognizes five winners across in-market beauty brands, early-stage concepts, fragrance innovation, creative design, and women’s entrepreneurship.


(BUSINESS WIRE) -- The Estée Lauder Companies, in partnership with Nykaa and Startup India, an initiative of the Department for Promotion of Industry and Internal Trade (DPIIT) within India’s Ministry of Commerce and Industry, announced the winners of BEAUTY&YOU India 2026, the country’s leading beauty entrepreneurship program.


For five years, BEAUTY&YOU India has discovered, supported, and accelerated India’s next generation of beauty entrepreneurs. Since launching in 2022, the program has helped founders and innovators develop their ideas and build their businesses by providing funding, mentorship, beauty industry expertise, distribution support, and strategic opportunities.


Stéphane de La Faverie, President and CEO, The Estée Lauder Companies, said: “India is one of the most exciting and inspiring forces in global beauty. We have a deep admiration for the country’s creativity, talent, culture, and entrepreneurial energy—and for the way India continues to shape and inspire beauty around the world. As BEAUTY&YOU India marks its fifth year, it reflects our long-term commitment to supporting the entrepreneurs behind the next generation of beauty. We are proud to recognize this year’s winners and celebrate the ideas that will define beauty in India and beyond.”


Nadine Graf, President, EUKEM (Europe, UK&I, and Emerging Markets), The Estée Lauder Companies, added: “Five years into BEAUTY&YOU India, what excites me most is the extraordinary creativity and ambition we continue to discover across the country. From emerging founders in smaller cities to women entrepreneurs building businesses with real impact, India is showing us just how much innovation can come from understanding local consumers, culture, and needs. Our ambition at The Estée Lauder Companies is to help unlock that potential—connecting Indian talent with global expertise, mentorship, and opportunities, and giving the next generation of beauty entrepreneurs the platform to shape the future of beauty, not only in India, but around the world.”


The 2026 winners join a growing community of founders whose ideas are shaping the future of beauty globally.


2026 BEAUTY&YOU India Winners


GROW: Best in-market beauty brand.


Laani – Nirja Bhatt, Founder & CEO: High-performance sweat and odor control products created for Indian heat, humidity, and skin. Led by a water-based clear deodorant stick that dries instantly, leaves no residue, and addresses underarm pigmentation, Laani is reimagining an everyday essential and addressing an underserved need for Indian women.


IMAGINE: Best early-stage beauty concept.


Boldpurity – Khatija Shabana, CEO, and Syed Mohammad Fouzan, Director: A scientist-led skincare concept developing proprietary formulation technologies to enhance the delivery and performance of established, active ingredients on skin.


BREAKTHROUGH: Best innovation in fragrance, presented by The Estée Lauder Companies’ Fragrance Atelier in Paris.


Goyam Green Tech – Ajaykumar Mehta, Shriya Rambhia, and Dheer Rambhia, Directors: A green chemistry platform leveraging biobased materials and chemistry to unlock high-performing fragrance solutions across formulation, format, and consumer experiences.


DESIGN: Recognizing creative talent with the potential to collaborate with a brand from The Estée Lauder Companies.


De Icebreaker Creative Studio – Pankti Sheth, Founder & Creative Director: A packaging and brand design studio that creates culturally aware and commercially relevant designs for brands across consumer categories, helping brands build meaningful experiences that resonate locally and compete globally.


VISIONARY WOMEN’S AWARD: Recognizing an outstanding woman entrepreneur driving innovation and impact in beauty, presented with Startup India, DPIIT.


Agapi Sikkim – Rinzing Choden Bhutia, Founder: A Himalayan skincare and lifestyle brand that provides employment and training to women in Sikkim, creating opportunities for women’s economic participation and financial independence in India’s Northeast.


Returning for the second year, the Visionary Women’s Award reflects The Estée Lauder Companies’ and Startup India’s shared commitment to advancing women founders and strengthening pathways for women to lead.


Shri Ateesh Kumar Singh, Additional Secretary, Startup India, DPIIT, said: “India’s startup ecosystem is a powerful engine of innovation and entrepreneurship, and BEAUTY&YOU India has become an important platform for supporting the next generation of beauty founders. As the program marks its fifth year, we commend The Estée Lauder Companies for its continued commitment to fostering innovation in India. The Visionary Women’s Award is a valuable initiative that recognizes women founders who are driving meaningful impact through innovation and leadership. Congratulations to all the winners, whose achievements reflect the creativity, ambition, and global potential of India’s innovation ecosystem.”


The 2026 edition introduced the DESIGN category, recognizing creative talent reimagining how beauty comes to life through packaging, retail, and consumer experiences. The new category reflects the important role creative expression plays in shaping how consumers discover and engage with beauty.


This year, the BREAKTHROUGH category focused on fragrance innovation and was led by The Estée Lauder Companies’ Fragrance Atelier in Paris, the Company’s global innovation hub dedicated to fragrance expertise. The category connects India’s rich legacy of fragrance craftsmanship with the Atelier’s global innovation ecosystem.


The winners were announced at an event in Mumbai featuring remarks from The Estée Lauder Companies’ leadership, including Akhil Shrivastava (Executive Vice President & Chief Financial Officer), Aude Gandon (Chief Digital & Marketing Officer), René Lammers (Executive Vice President, Chief Research & Innovation Officer), and Nadine Graf (President, EUKEM – Europe, UK&I, and Emerging Markets); Nykaa’s Anchit Nayar (Executive Director & CEO, Nykaa Beauty); Shri Ateesh Kumar Singh, Additional Secretary, Startup India, DPIIT; and industry leader Gaurav Gupta (Couturier, Artist, and Designer, Gaurav Gupta Studio).


Anchit Nayar, Executive Director & CEO, Nykaa Beauty, said: “India’s beauty ecosystem is evolving rapidly, shaped by a new generation of founders bringing fresh perspectives, innovative ideas and a deeper understanding of the Indian consumer. At Nykaa, we’ve seen how brands that combine a clear consumer proposition with a strong understanding of the market can build meaningful connections and create lasting businesses. Through BEAUTY&YOU India, we’re proud to partner with The Estée Lauder Companies in supporting entrepreneurs who are bringing new ideas to life and contributing to the next phase of growth in India’s beauty industry.”


BEAUTY&YOU India is part of The Estée Lauder Companies’ broader commitment to India, built over more than two decades of serving consumers and partnering across the country’s beauty ecosystem. As India’s influence on beauty continues to expand, The Estée Lauder Companies is proud to help support the talent and innovation that will define the industry’s next chapter.


About The Estée Lauder Companies


The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary, NIOD, Avestan and Loopha, and Balmain Beauty.


ELC-C


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20261015612324/en/



Permalink

https://aetoswire.com/en/news/1610202658122


Contacts

Media Relations:

Brendan Riley

briley@estee.com

TestMu AI Brings Real Device Testing to Kane CLI, Letting Developers Test Mobile Apps on Real Phones From Any Terminal

 Plain-English mobile tests now run on real Android and iOS devices in the TestMu AI cloud from any Mac, Windows, or Linux machine, with a live view of the device on the developer's laptop


 


(BUSINESS WIRE)--TestMu AI (formerly LambdaTest), the Full Stack Agentic AI Quality Engineering platform, announced real device support in Kane CLI. Developers can now test a mobile app on a real phone or tablet in the TestMu AI cloud straight from the terminal: they type what to test in plain English, and Kane taps through the app on a real Android or iOS device.


Until now, testing a mobile app on real hardware meant keeping a drawer of phones, or a separate device farm outside the developer's workflow. With real device support, Kane CLI removes that dependency again now by giving terminal-first access to the real device cloud. Kane CLI on real devices gives teams:


Real Android and iOS devices from any terminal. Kane CLI opens a real device in the TestMu AI cloud and taps through the app from natural language prompts. Developers pick a model and OS version, or let the cloud assign any available device.

A live view of the device. The real device's screen opens in its own window on the developer's laptop and updates live as Kane CLI taps, so teams can watch the test as it runs.

Saved, replayable tests. Each run becomes a saved test that can be replayed later without the AI re-deciding each tap, and re-run on the cloud grid at scale with a single command.

Results in Test Manager. Every test, its steps, and screenshots land in TestMu AI Test Manager, like every other Kane test.

Less setup. Android permissions and iOS alerts are handled automatically, and app builds (.apk, .aab, .ipa) upload once and are reused across runs.

"Real device testing has always been the part of mobile QA that teams put off because it needed hardware, a Mac, and a separate tool. We wanted it to be one line in the terminal," said Mudit Singh, Co-Founder, TestMu AI. "With Kane CLI, a developer on any laptop can describe a test in plain English, watch it run on a real phone in the cloud, and ship with the same confidence as a team with a full device lab."


Real device support is available today in Kane CLI 0.9.0 and later for customers on KaneAI Max or KaneAI credits with Real Device Plus Automation Cloud. To get started, visit testmuai.com/kane-cli.


About TestMu AI


TestMu AI (formerly LambdaTest) is a Full Stack Agentic AI Quality Engineering platform that empowers teams to test intelligently and ship faster. AI-native by design, it offers end-to-end AI agents to plan, author, execute, and analyze software quality across web, mobile, and enterprise applications, on real devices, real browsers, and custom real-world environments. For more information, visit testmuai.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20261016998250/en/



Permalink

https://aetoswire.com/en/news/54623309


Contacts

Media Contact

Nikhil Saxena

Corporate Communication Manager, TestMu AI

nikhils@testmuai.com | +91 98709 81968

اقتصاد النتائج في بيئة العمل – بحث جديد من Vertage

  تحقق الشركات المهيأة لتحقيق النتائج أداءً أفضل في رضا العملاء، وتنفيذ الاستراتيجيات، وتسريع تحقيق القيمة، بفضل ثقافة مؤسسية تمنحها ميزة واضحة؛ ويكشف بحث جديد من Vertage عن أسرار هذا التفوق، والسبل المتاحة أمام الشركات الأخرى للحاق بالركب


 


(BUSINESS WIRE)-- كشف بحث عالمي جديد أجرته Vertage، الشركة الرائدة في مجال تكنولوجيا الموارد البشرية، أن ثلاث من كل أربع مؤسسات (74%) تحدد الأعمال ذات الأهمية انطلاقًا من النتائج، في حين لا تتجاوز نسبة المؤسسات المستعدة لتحقيق هذه النتائج بصورة متسقة 15%. تسجّل المؤسسات "المهيأة لتحقيق النتائج" مستويات أعلى من رضا العملاء (91% مقابل 67%)، ومعدلات أفضل في تحقيق الأهداف الاستراتيجية (86% مقابل 65%)، وسرعة أكبر في تحويل الفرص إلى قيمة ملموسة (85% مقابل 64%). وتتمتع هذه المؤسسات أيضًا بميزة ثقافية واضحة؛ إذ يدرك 69% من موظفيها دورهم وإسهامهم في تحقيق الأهداف، ويتمتعون بالقدرة على تكييف أساليب عملهم وفقًا للمتطلبات المتغيرة، مقارنةً بـ 34% فقط في المؤسسات الأخرى.


"لم يعد اعتماد الذكاء الاصطناعي هو ما يصنع الفارق بين الشركات القوية وغيرها، بل باتت الجاهزية والقدرة على تحقيق النتائج هي العامل الحاسم"، صرّح بذلك Edzard Overbeek، الرئيس التنفيذي لشركة Vertage. "تُنسّق الشركات الأكثر نجاحًا جهود موظفيها وشركائها وإمكانات الذكاء الاصطناعي وتوجّهها نحو تحقيق نتائج واضحة، مع إبقاء التقدير البشري في صميم عملية اتخاذ القرار".


تستند دراسة "اقتصاد النتائج في بيئة العمل" إلى بيانات جُمعت من 800 من صُنّاع القرار في المؤسسات و1,200 موظف في ستة أسواق، إضافةً إلى مقابلات متعمقة مع قيادات تنفيذية رفيعة المستوى. وتخلص الدراسة إلى نتيجة واضحة: أصبح العمل القائم على تحقيق النتائج نهجًا سائدًا، لكن الجاهزية اللازمة لتحقيق هذه النتائج لا تزال محدودة الانتشار. يكشف التقرير العوامل التي تميّز المؤسسات المهيأة لتحقيق النتائج، ويقدّم إرشادات عملية لربط المسؤولية عن تحقيق النتائج بالأنظمة والثقافة المؤسسية والتكنولوجيا وقرارات إدارة القوى العاملة، بما يسهم في رأب الفجوة القائمة.


 كيف ينظّم الروّاد العمل وينفّذونه بفاعلية


 يحدّد التقرير ثلاثة أبعاد للجاهزية لتحقيق النتائج: البُعد الهيكلي، ويتمثل في تنظيم المسؤوليات والاستثمارات والقرارات بما يخدم النتائج المستهدفة؛ والبُعد التشغيلي، ويقوم على توظيف الموظفين والمتخصصين والشركاء والذكاء الاصطناعي ضمن منظومة متكاملة؛ والبُعد الثقافي، الذي يوفّر للأفراد الوضوح والثقة والصلاحيات اللازمة لتكييف أساليب عملهم.


تخطط المؤسسات المهيأة لتحقيق النتائج لتنفيذ أعمالها وفق استراتيجية موحّدة تشمل الموظفين والشركاء والمورّدين والذكاء الاصطناعي (بنسبة 57% مقابل 40% بين المؤسسات عمومًا).

تزيد احتمالية قياس هذه المؤسسات للتكلفة الإجمالية اللازمة لتحقيق النتائج (55% مقابل 31% لدى المؤسسات الأخرى).

تعني الجاهزية لتحقيق النتائج أيضًا توظيف إمكانات الذكاء الاصطناعي للارتقاء بتجربة الموظفين في بيئة العمل. ومع ذلك، يرى 71% من صُنّاع القرار أن الذكاء الاصطناعي عزّز القدرات المؤسسية، مقابل 43% فقط من الموظفين، بفارق قدره 28 نقطة مئوية، وهو ما يشير إلى أن اعتماد هذه التقنيات يتقدم بوتيرة أسرع من إعادة تصميم العمل للاستفادة منها.

ويتيح ذلك للقيادات اتخاذ قرارات مدروسة بشأن بناء القدرات داخليًا، أو الحصول عليها من خلال شريك خارجي، أو الاستعانة بكفاءات مرنة، أو توظيف الذكاء الاصطناعي لأتمتة المهام.


وكما أفاد أحد القيادات المؤسسية الذين أُجريت معهم مقابلات لإعداد التقرير: "لا يهمني عدد الأشخاص الذين تستعين بهم لتنفيذ العمل؛ ما يهمني هو أن تكون النتيجة النهائية بالمستوى المطلوب". فالنتيجة المنشودة هي التي تحدد معايير الأداء الجيد، أما نموذج التنفيذ فيمكن تكييفه بما يتناسب معها.


 الثقافة المؤسسية: العامل الحاسم في تحقيق النتائج


تجعل الثقافة المؤسسية من القدرات البشرية مصدرًا للميزة التنافسية. فالعوامل الحاسمة لا تقتصر على التكنولوجيا، بل تشمل وضوح الأهداف، والثقة، وتمكين الأفراد من إعمال تقديرهم عند اتخاذ القرارات. وتجسّد تجارب العملاء ذلك عمليًا؛ إذ منحت إحدى الشركات فرق العمل متعددة التخصصات صلاحية تحقيق نتائج محددة ضمن دورات عمل مدتها 90 يومًا، بينما جعلت شركة أخرى مراجعة مخرجات الذكاء الاصطناعي والتشكيك فيها عند الحاجة جزءًا من مهام الموظفين، ما ساعدهم على اكتشاف الأخطاء في مراحل مبكرة وتعزيز الثقة والدقة.


وقال Overbeek: "تبدأ الجاهزية لتحقيق النتائج من الثقافة المؤسسية". وأضاف: "يحتاج الأفراد إلى فهم النتائج المنشودة، ومعرفة المجالات التي يمكنهم فيها إبداء الاعتراض أو التشكيك في القرارات، والشعور بالثقة التي تتيح لهم إعمال تقديرهم الشخصي. ويساعد هذا الوضوح المؤسسات على اتخاذ قرارات أفضل بشأن كيفية إنجاز العمل".


 رأب الفجوة في الجاهزية لتحقيق النتائج


تساعد أداة التشخيص التي طوّرتها Vertage، والمكوّنة من خمس مراحل، القيادات على تحديد موقع مؤسساتهم في مسار الانتقال من نموذج العمل القائم على الموارد إلى نموذج يركّز على تحقيق النتائج، مع توضيح المراحل الوسيطة والتغييرين أو التغييرات الثلاثة التي يمكن أن تدفع المؤسسة إلى إحراز تقدم في هذا المسار.


وقالت Sarah White، مؤسسة شركة Lemon والمديرة الإدارية لها، وهي شركة مستقلة متخصصة في الاستراتيجيات والأبحاث في مجال تكنولوجيا الموارد البشرية واستقطاب المواهب، وأحد المساهمين في إعداد التقرير: "لا تكمن الخلاصة الأهم لهذا البحث في أن نسبة محدودة فقط من المؤسسات تمتلك الجاهزية اللازمة لتحقيق النتائج، بل في أن الغالبية العظمى منها تمر بتحول جوهري في كيفية تنظيم العمل. ولا يُشترط أن تكون كل شركة قد رسمت اليوم ملامح نموذج التشغيل الذي ستتبناه مستقبلاً بكل تفاصيله. فما يهم حقًا هو أن تحدد مواطن الفجوة بوضوح، وأن تبدأ في اتخاذ خطوات مدروسة لإحداث التغيير اللازم وسدّ هذه الفجوات تدريجيًا".


 اكتشف مدى جاهزية شركتك لتحقيق النتائج، وحدّد الخطوات التالية اللازمة لتعزيز أدائها. نزِّل التقرير واستخدم أداة التشخيص المكوّنة من خمس مراحل لتقييم جاهزية مؤسستك لتحقيق النتائج من هنا.


 سيتناول التقرير المقبل الصادر عن Vertage سبل حفاظ المؤسسات على الميزة البشرية في ظل إعادة تشكيل الذكاء الاصطناعي للأعمال المبتدئة، وفرص التعلّم والتطور الوظيفي، ومسارات التقدم المهني، وأشكال التعاون بين الإنسان والذكاء الاصطناعي.


 نبذة عن Vertage


تتمثل رؤية Vertage في أن تصبح المحرّك الذي يعزّز القدرات ويُعيد صياغة أساليب إنجاز العمل. وبالجمع بين الكفاءات المتخصصة والذكاء الاصطناعي في المزيج الأمثل، تسعى Vertage إلى تمكين الأفراد والشركات من تسريع وتيرة الإنجاز، وتوسيع آفاق التفكير، والحفاظ على ريادتهم في عصر الذكاء. واستنادًا إلى عقود من الخبرة في إدارة القوى العاملة، وأطر حوكمة بمستوى المؤسسات الكبرى، وشبكة عالمية تضم 1.5 مليون متخصص في مختلف المجالات موزعين على 80 دولة، تساعد Vertage الشركات على تجاوز تحديات استقطاب المواهب وإنجاز الأعمال بسرعة أكبر، وذكاء أعلى، وتحكم أكثر فاعلية. وبفضل قيمة إجمالية للفواتير تبلغ 10 مليارات دولار، تسعى Vertage إلى تحويل الرؤى إلى خطوات عملية، وتحويل كل تعاون إلى قوة دافعة نحو آفاق جديدة من النمو.


 منهجية البحث


أجرت شركة Opinium Research استبيانًا عبر الإنترنت استغرق 15 دقيقة خلال الفترة من 6 إلى 24 يوليو 2026، وشمل 800 من صُنّاع القرار في المؤسسات و1,200 من العاملين بعقود محددة المدة، وذلك في الولايات المتحدة والمملكة المتحدة وأيرلندا وأستراليا والهند وبلجيكا وهولندا. شغل المشاركون من صُنّاع القرار مناصب ضمن الإدارة التنفيذية العليا، أو كانوا مسؤولين عن اتخاذ القرارات المتعلقة بالمشتريات أو التكنولوجيا، وعملوا في مؤسسات تضم ما لا يقل عن 1,000 موظف، أو ما لا يقل عن 2,000 موظف في الولايات المتحدة. كما شمل البحث 10 مقابلات معمّقة، استغرقت كل منها 45 دقيقة، مع عدد من كبار صُنّاع القرار لدى عملاء Vertage، ممن يتولون مسؤولية اتخاذ القرارات المتعلقة بالمشتريات أو التكنولوجيا أو استراتيجية القوى العاملة أو التحول المؤسسي أو تنفيذ المشروعات الكبرى، أو يؤثرون في هذه القرارات.  


إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.



الرابط الثابت

https://www.aetoswire.com/ar/news/54622681


جهات الاتصال

التواصل الإعلامي

 Alice MacDonald

 مديرة الاتصالات

 Alice.macdonald@hotwireglobal.com

MSCI Launches a Consultation on a Proposal to Reclassify Indonesia from Emerging Market to Standalone Market Status

 MSCI to consult on proposal to reclassify the MSCI Indonesia Indexes to Standalone Market status

Existing freeze on Indonesian securities in MSCI Indexes to remain in place until further notice

 


(BUSINESS WIRE) -- MSCI announced the launch of a consultation on a proposal to reclassify the MSCI Indonesia Indexes from Emerging Market to Standalone Market status. MSCI will announce its final decision by the end of June 2027 and may provide an interim update on market participant feedback during the consultation period.


As part of the June 2026 Market Classification Review, MSCI reported that market participants had raised significant concerns regarding the investability of the Indonesian equity market, including persistent opacity in shareholding structures and suspected coordinated trading behavior. While the Indonesian authorities have announced reforms, including enhanced disclosure of shareholders with ownership above 1%, more granular investor classification disclosure, High Shareholding Concentration (HSC) reporting, and a roadmap towards a minimum free float requirement of 15%, institutional investors have emphasized the need for consistent implementation and evidence of sustained material impact from these announcements. MSCI indicated in June that if sufficient progress was not evident by the November 2026 Index Review, MSCI would consider launching a consultation on reclassifying the Indonesian market.


Market participants have indicated to MSCI that, to date, sufficient progress has not been observed consistently across the Indonesian equity market. Despite the announced reforms, significant concerns remain around market dysfunction, including continued suspected coordinated trading behavior and lack of evidence of meaningful enforcement.


Accordingly, MSCI considers Indonesia’s continued classification as an Emerging Market no longer appropriate and is launching a consultation on a proposal to reclassify Indonesia as a Standalone Market. Feedback from market participants suggests that a reclassification to Frontier Markets would not properly recognize the depth of the market problems. MSCI expects to proceed with the proposed reclassification unless the consultation identifies clear evidence of material improvements in market governance and functioning to warrant reconsideration.


MSCI will continue applying the existing freeze on certain index related changes for Indonesian securities resulting from Index Reviews or corporate events until further notice. Under this treatment, MSCI will not implement increases to Foreign Inclusion Factors (FIF) or Number of Shares (NOS), additions to the MSCI Indonesia Investable Market Index (IMI) or upward migrations across size-segment indexes.


MSCI will continue to delete securities identified by the Indonesian authorities under the HSC framework and to use the 1% shareholder disclosure data to adjust free float estimates.


MSCI welcomes feedback from market participants on this reclassification proposal for the MSCI Indonesia Indexes until April 30, 2027 and will announce its decision on or before June 30, 2027. Further details may be found in the consultation document available at https://www.msci.com/index-consultations. To participate in the consultation, please provide your feedback by e-mail to clientservice@msci.com.


-Ends-


About MSCI


MSCI. Inc. (NYSE: MSCI) strengthens global markets by connecting participants across the financial ecosystem with a common language. Our research-based data, analytics and indexes, supported by advanced technology, set standards for global investors and help our clients understand risks and opportunities so they can make better decisions and unlock innovation. We serve asset managers and owners, private-market sponsors and investors, hedge funds, wealth managers, banks, insurers and corporates. To learn more, please visit www.msci.com.


The process for submitting a formal index complaint can be found on the index regulation page of MSCI’s website at: https://www.msci.com/index-regulation.


 

 

The data, data feeds, databases, reports, text, graphs, charts, images, videos, recordings, models, metrics, analytics, indexes, ratings, scores, cases, estimates, assessments, software, websites, products, services and other information and materials contained herein or delivered in connection with this notice (collectively, the “Information”) are copyrighted, trade secrets (when not publicly available), trademarks and proprietary property of MSCI Inc. or its subsidiaries (collectively, “MSCI”), MSCI’s licensors, direct or indirect suppliers and authorized sources, and/or any third party contributing to the Information (collectively, with MSCI, the “Information Providers”). All rights in the Information are reserved by MSCI and its Information Providers and user(s) shall not, nor assist others to, challenge or assert any rights in the Information.

 

Unless you contact MSCI and receive its prior written permission, you must NOT use the Information, directly or indirectly, in whole or in part (i) for commercial purposes, (ii) in a manner that competes with MSCI or impacts its ability to commercialize the Information or its services, (iii) to provide a service to a third party, (iv) to permit a third party to directly or indirectly access, use or resell the Information, (v) to redistribute or resell the Information in any form, (vi) to include the Information in any materials for public dissemination such as fund factsheets, market presentations, prospectuses, and investor information documents (e.g. KIIDs or KIDs), (vii) to create or as a component of any financial products (including any digital assets, tokenized funds or other tokenized or blockchain-based products), whether listed or traded over the counter or on a private placement basis or otherwise, (viii) to create, enhance or optimize any indexes, ratings or other data products, including in derivative works combined with other indexes or data or as a policy, product or performance benchmarks for active, passive or other financial products, (ix) to populate a database, (x) to train, use as an input to, or otherwise in connection with any artificial intelligence, machine learning, large language models or similar technologies except as licensed and expressly authorized under MSCI’s AI Contracting Supplement at https://www.msci.com/legal/supplemental-terms-for-client-use-of-artificial-intelligence, or (xi) to access or extract the Information using unauthorized bots, scrapers, crawlers, AI agents, MCP servers or connectors, or other automated means, or to circumvent any technical protections.


 

The intellectual property rights of MSCI and its Information Providers may not be misappropriated or used in a competitive manner through the use of third-party data or financial products linked to the Information, including by using an MSCI index-linked future or option in a competing third-party index to provide an exposure to the underlying MSCI index or by using an MSCI index-linked ETF or other tokenized or digital instrument, directly or indirectly, to create a financial product that provides an exposure to the underlying MSCI index without obtaining a license from MSCI.


 

The user or recipient of the Information assumes the entire risk of any use it may make, permit or cause to be made of the Information. NONE OF THE INFORMATION PROVIDERS MAKES ANY EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE INFORMATION (OR THE RESULTS TO BE OBTAINED BY THE USE THEREOF), AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, EACH INFORMATION PROVIDER EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES (INCLUDING ANY IMPLIED WARRANTIES OF ORIGINALITY, ACCURACY, TIMELINESS, SUITABILITY, NON-INFRINGEMENT, COMPLETENESS, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO ANY OF THE INFORMATION. Without limiting any of the foregoing and to the maximum extent permitted by applicable law, in no event shall MSCI or any other Information Provider have any liability arising out of or relating to any of the Information, including for any direct, indirect, special, punitive, consequential (including lost profits) or any other damages, even if notified of the possibility of such damages. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited.


 

The Information, including index construction, ratings, historical data, or analysis, is not a prediction or guarantee of future performance, and must not be relied upon as such. Past performance is not indicative of future results. The Information may contain back tested data. Back-tested performance based on back-tested data is not actual performance but is hypothetical. There are frequently material differences between back tested performance results and actual results subsequently achieved by any investment strategy. The Information may include “Signals,” defined as quantitative attributes or the product of methods or formulas that describe or are derived from calculations using historical data. Signals are inherently backward-looking because of their use of historical data, and they are inherently inaccurate, not intended to predict the future and must not be relied upon as such. The relevance, correlations and accuracy of Signals frequently change materially over time.


 

The Information may include data relating to indicative prices, evaluated pricing or other information based on estimates or evaluations (collectively, “Evaluations”) that are not current and do not reflect real-time traded prices. No evaluation method, including those used by the Information Providers, may consistently generate evaluations or estimates that correspond to actual “traded” prices of any relevant securities or other assets. Evaluations are subject to change at any time without notice and without any duty to update or inform you, may not reflect prices at which actual transactions or collateral calls may occur or have occurred. The market price of securities, financial instruments, and other assets can be determined only if and when executed in the market. There may be no, or may not have been any, secondary trading market for the relevant securities, financial instruments or other assets. Private capital, equity, credit and other assets and their prices may be assessed infrequently, may not be priced on a secondary market, and shall not be relied upon as an explicit or implicit valuation of a particular instrument. Any reliance on fair value estimates and non-market inputs introduces potential biases and subjectivity. Internal Rate of Return metrics are not fully representative without full disclosure of fund cash flows, assumptions, and time horizons.


 

The Information does not constitute, and must not be relied upon as, investment advice, credit ratings, or proxy advisory or voting services. None of the Information Providers, their products or services, are fiduciaries or make any recommendation, endorsement, or approval of any investment decision or asset allocation. Likewise, the Information does not represent an offer to sell, a solicitation to buy, or an endorsement of any security, financial product, instrument, investment vehicle, or trading strategy, whether or not linked to or in any way based on any MSCI index, rating, subcomponent, or other Information (collectively, “Linked Investments”).The Information should not be relied on and is not a substitute for the skill, judgment and experience of any user when making investment and other business decisions. MSCI is not responsible for any user’s compliance with applicable laws and regulations. All Information is impersonal, not tailored to the needs of any person, entity or group of persons, not objectively verifiable in every respect, and may not be based on information that is important to any user.


 

It is not possible to invest in an index. Exposure to an asset class or trading strategy or other category represented by an index is only available through third party investable instruments (if any) based on that index. MSCI makes no assurance that any Linked Investments will accurately track index performance or provide positive investment returns. Index returns do not represent results of actual trading of investible assets/securities. MSCI maintains and calculates indexes but does not manage assets. The calculation of indexes and index returns may deviate from the stated methodology. Index returns do not reflect payment of any sales charges or fees an investor may pay to purchase securities underlying the index or Linked Investments. The imposition of these fees and charges would cause the performance of a Linked Investment to be different than the MSCI index performance.


 

Information provided by MSCI Solutions LLC and certain related entities (“MSCI Solutions”), including materials utilized in MSCI sustainability and climate products, have not been submitted to, nor received approval from any regulatory body. MSCI sustainability and climate offerings, research and data are produced by, and ratings are solely the opinion of MSCI Solutions. For regulatory disclosures mandated under the EU ESG Rating Activities Regulation (Regulation (EU) 2024/3005), please visit www.msci.com/legal/sustainability-and-climate-resources-and-disclosures for methodology and organizational disclosures and https://one.msci.com for rating level disclosures. Other MSCI products and services may utilize information from MSCI Solutions, Barra LLC or other affiliates. More information can be found in the relevant methodologies on www.msci.com. MSCI Indexes are administered by MSCI Limited (UK) and MSCI Deutschland GmbH. No regulated use of any MSCI private real assets indexes in any jurisdiction is permitted without MSCI’s express written authorization. The process for applying for MSCI’s express written authorization can be found at: https://www.msci.com/index-regulation.


 

MSCI receives compensation in connection with licensing its indexes and other Information to third parties. MSCI Inc.’s revenue includes fees based on assets in Linked Investments. Information can be found in MSCI Inc.’s company filings on the Investor Relations section of msci.com. Issuers mentioned in MSCI Solutions materials or their affiliates may purchase research or other products or services from one or more MSCI affiliates, manage financial products such as mutual funds or ETFs rated by MSCI Solutions or its affiliates or are based on MSCI Indexes. Constituents of MSCI equity indexes are listed companies, which are included in or excluded from the indexes according to the application of the relevant index methodologies. Constituents in MSCI Inc. equity indexes may include MSCI Inc., clients of MSCI or suppliers to MSCI. MSCI Solutions has taken steps to mitigate potential conflicts of interest and safeguard the integrity and independence of its research and ratings.


 

MIFID2/MIFIR notice: MSCI Solutions does not distribute or act as an intermediary for financial instruments or structured deposits, nor does it deal on its own account, provide execution services for others or manage client accounts. No MSCI product or service supports, promotes or is intended to support or promote any such activity. MSCI Solutions is an independent provider of sustainability and climate data. All use of indicative prices for carbon credits must comply with any rules specified by MSCI. All transactions in carbon credits must be traded “over-the-counter” (i.e. not on a regulated market, trading venue or platform that performs a similar function to a trading venue) and result in physical delivery of the carbon credits.


 

You may not remove, alter, or obscure any attribution to MSCI or notices or disclaimers that apply to the Information. MSCI, Barra, RiskMetrics, and other MSCI brands and product names are the trademarks, service marks, or registered trademarks of MSCI or its subsidiaries in the United States and other jurisdictions. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P Dow Jones Indices. “Global Industry Classification Standard (GICS)” is a service mark of MSCI and S&P Dow Jones Indices. Terms such as including, includes, for example, such as and similar terms used herein are without limitation.


 

MSCI and its Information Providers may use automated technologies and artificial intelligence to help generate content and output incorporated in the Information. Content generated using such technologies may contain errors or inaccuracies.


 

Privacy notice: For information about how MSCI collects and uses personal data, please refer to our Privacy Notice at: https://www.msci.com/privacy-pledge. For copyright infringement claims contact us at dmca@msci.com. This notice is governed by the laws of the State of New York without regard to conflict of laws principles.


 


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20261015590610/en/



Permalink

https://www.aetoswire.com/en/news/1610202658128


Contacts

Media Inquiries

PR@msci.com

Melanie Blanco +1 212 981 1049

Konstantinos Makrygiannis +44 77 6893 0056

Tina Tan +852 2844 9320


MSCI Global Client Service

EMEA Client Service + 44 20 7618 2222

Americas Client Service +1 888 588 4567

Asia Pacific Client Service + 852 2844 9333

Friday, October 16, 2026

Dubai Culture: Dubai ranks first globally in attracting new FDI projects in cultural and creative industries in 2025

 Dubai, United Arab Emirates - Friday, 16. October 2026 AETOSWire Print 



 


Dubai Culture and Arts Authority has revealed that Dubai retained its position as the world’s leading destination for new foreign direct investment (FDI) projects in the cultural and creative industries (CCIs) in 2025, ranking first globally for the fourth consecutive year. According to data from the Financial Times’ fDi Markets, a leading source of greenfield FDI intelligence, Dubai topped the ranking of 233 cities, ahead of London, Singapore, Riyadh and Bengaluru. The results reflect the strength of the emirate’s investment environment and its appeal to creative businesses, investors, entrepreneurs and talent from around the world.


In 2025, Dubai attracted 754 new projects in the cultural and creative industries, with greenfield FDI capital inflows reaching US$3.756 billion and generating 19,304 jobs. Based on the Financial Times’ definition of creative industries, the emirate ranked first globally for both project numbers and job creation, and second for greenfield FDI capital inflows.


Growth spanned advertising and public relations; specialised computer programming; data processing and digital services; film, media and gaming; AI-powered creative technologies; creative education; professional services; design and architecture; crafts; performing arts; and museums and historical sites. This breadth reflects the diversity of Dubai’s creative economy and its capacity to respond to technological and economic change.


India was the largest source of greenfield FDI capital inflows into Dubai’s cultural and creative industries, accounting for 19% of the total, followed by the United States at 17.5%, China at 13%, Malaysia at 12%, and the United Kingdom at 9%. By project numbers, the United Kingdom led with a 21.5% share, followed by India at 21%, the United States at 14% and France at 4%.


Dubai’s performance was supported by an investment environment offering full foreign ownership, efficient business setup, specialised creative and technology clusters, long-term residency pathways for talent, advanced digital and logistics infrastructure, and access to regional and international markets. Alongside the Dubai Economic Agenda D33 and the Dubai Creative Economy Strategy, these advantages support business growth and strengthen the emirate’s position as a destination for investment in the cultural and creative industries.



Permalink

https://www.aetoswire.com/en/news/dcaa16102026e


Contacts

Antoine Boghos


antoine@ciceroandbernay.com

Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World


 Abu Dhabi United Arab Emirates - 

Abu Dhabi has launched TAMM Global, a private technology company established to make the award-winning technology behind TAMM available to governments worldwide.


It is the first time the AI-powered platform, which serves 4.7 million users and is recognized as one of the world’s most advanced digital government platforms, will be available for international licensing and deployment.


The launch marks a significant milestone in Abu Dhabi’s ambition to become the world’s first AI-native government. It reflects growing international demand for proven technologies that can accelerate digital transformation while protecting sovereignty, regulatory compliance and public trust. It also demonstrates how homegrown innovation and intellectual property are creating opportunities well beyond Abu Dhabi’s borders.


Ahmed Tamim Hisham Al Kuttab, Chairman of the Department of Government Enablement – Abu Dhabi, said: “TAMM was created in Abu Dhabi for one reason: to improve lives. Today, it serves millions of users and has become an integral part of how people and businesses interact with government. Through TAMM Global, we are building on that success by making capabilities developed and proven in Abu Dhabi available to governments seeking to deliver better outcomes for their people.”


Since launching in 2005, TAMM has evolved into the digital gateway to government services in Abu Dhabi. It combines more than 1,200 public and private sector services and saves each user approximately nine visits to government service centers per year – returning an estimated 12 hours to every person and business annually. TAMM currently achieves a customer satisfaction score of 94.5% – up from 78% in 2022, before AI was integrated into the app. It has also cut the cost of providing services by 30%, with most savings coming within the first year.


Services available through TAMM include setting up a business entirely through the app, including opening a business bank account, managing investment portfolios, renewing identity documents, completing vehicle registrations and accessing a wide range of everyday government services. TAMM AutoGov, announced in 2025 as the world’s first AI public servant, can proactively renew licenses, settle payments and book routine healthcare appointments without requiring users to initiate the process themselves.


Through TAMM Global, governments will gain access to the technology, operating model and implementation expertise behind one of the world’s most advanced digital government platforms. The platform includes a library of pre-built government services, journeys and digital capabilities that can be adapted to local laws, regulations and operating requirements, helping governments deploy faster and with less implementation complexity.


AI is embedded throughout the platform, including service discovery, automation, decision support, service delivery and AI-enabled service rendering. This allows governments to offer more proactive, personalized and efficient experiences.


Each deployment can be configured for adopting governments’ own languages, laws and institutions. TAMM Global supports multilingual and sovereign deployment models, allowing governments to retain full control over their data, infrastructure, policies and citizen services while benefiting from proven technology already deployed at scale.


The company will license the platform architecture, implementation methodologies and operational expertise that enabled Abu Dhabi to build and operate TAMM at scale. By combining pre-built capabilities with proven implementation methods and operating practices refined through millions of real-world interactions, TAMM Global can help governments accelerate deployment without having to build an equivalent platform from scratch.


As an independent private-sector company, TAMM Global will be able to partner directly with governments, organizations and institutions worldwide.


TAMM’s innovation and impact have earned international recognition. In 2025, it was named the world’s best e-Government initiative at the UN-backed World Summit on the Information Society (WSIS) Prizes. In 2026, it won the Government category across Europe, the Middle East and Asia in the Gartner Eye on Innovation Awards.



Permalink

https://www.aetoswire.com/en/news/1610202658118


Contacts

Dean Wilkins 


dwilkins@apcoworldwide.com

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1


 OSAKA, Japan & CAMBRIDGE, Mass. -

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW)


− Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role


− ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide


(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1.


“We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5


NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disrupted nighttime sleep, sleep paralysis, hallucinations and cognitive symptoms. Many patients experience challenges that may affect their quality of life and limit their independence. People with narcolepsy have approximately twice the rate of healthcare resource utilization compared with controls, including more frequent emergency department visits, hospitalizations, outpatient appointments and physician consultations.6,7,8


ORZEYFUL is the first therapy designed to restore orexin signaling and address the biological cause of NT1. This mechanism represents a potential paradigm shift from symptom management to a disease-targeted treatment. Landmark Phase 3 studies in people with NT1 demonstrated ORZEYFUL improved the full range of NT1 symptoms and quality of life compared with placebo9. Results showed consistent, clinically meaningful and statistically significant improvements with ORZEYFUL compared to placebo in wakefulness, sleepiness, cataplexy, disease severity and quality of life measures (p-values of <0.001) across doses over 12 weeks. These improvements were observed at the earliest assessed timepoint for each measure and were sustained throughout the duration of the studies. ORZEYFUL was generally well-tolerated with a safety profile consistent across clinical studies to date. The most common side effects include insomnia, urinary urgency, urinary frequency and excessive saliva.


About ORZEYFUL (Oveporexton)


ORZEYFUL (oveporexton) is an oral orexin receptor 2 (OX2R) agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency associated with narcolepsy type 1 (NT1). By activating OX2Rs, ORZEYFUL promotes wakefulness and reduces abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy (sudden and temporary loss of muscle tone), and address a range of daytime and nighttime symptoms as evaluated in clinical studies and consistent with the approved label.


About Takeda's Orexin Franchise


Takeda is the leader in orexin science with a tailored portfolio of investigational orexin agonists in pre-clinical and clinical stages for multiple-sleep wake disorders and other indications where orexin plays a role including respiration, mood and metabolism. Oveporexton is the lead orexin receptor 2 (OX2R) agonist in Takeda’s orexin franchise and has been approved by regulatory bodies in China for the treatment of narcolepsy type 1(NT1) in adolescents aged 16 and older and adults as well as in the United States and Japan for adults with NT1. The company is also investigating other oral orexin agonists, including TAK-360 for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), as well as TAK-495.


About Takeda


Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.


Takeda Important Notice


For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.


The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


Takeda Forward-Looking Statements


This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at https://www.sec.gov/. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.


Takeda Medical Information


This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


References


Plazzi G, Dauvilliers Y, Pizza F, et al. Effect of the Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) on Functional Impacts of Narcolepsy Type 1: Results from Two Phase 3 Studies. Presented at: SLEEP 2026; 14-17 June 2026; Baltimore, MD.


Pizza F, Dauvilliers Y, Del Rio Villegas R, et al. Oveporexton (TAK-861) Improves Cognitive Symptoms in Patients with Narcolepsy Type 1: Results from Two Randomized, Placebo-controlled Phase 3 Trials. Presented at: SLEEP 2026; 14-17 June 2026; Baltimore, MD.


Barateau L, Gong Y, Dauvilliers Y, et al. Effects of Treatment with Oveporexton, an Orexin Receptor 2 Agonist, on Sleep in People with Narcolepsy Type 1: Phase 3 Results. Presented at: SLEEP 2026; 14-17 June 2026; Baltimore, MD.


Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13(3):419-425.


Flores NM, Villa KF, Black J, et al. The humanistic and economic burden of narcolepsy. J Clin Sleep Med. 2016;12(03):401-407.


Thorpy MJ and Hiller G. The medical and economic burden of narcolepsy: implications for managed care. Am Health Drug Benefits. 2017;10(5):233-241.


Jennum P, Ibsen R, Petersen ER, et al. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012;13(8):1086–93.


Black J, Reaven NL, Funk SE, et al. The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings. Sleep Med. 2014 May;15(5):522–9.


Dauvilliers Y, Mignot E, Antczak J, et al. Oveporexton for Narcolepsy Type 1: Results from Two Phase 3 Trials. New England Journal of Medicine 2026.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20261014922379/en/



Permalink

https://www.aetoswire.com/en/news/1510202658097


Contacts

Investor Relations

Christopher O’Reilly

takeda.ir.contact@takeda.com


Japanese Media

Tsuyoshi Tada

toiawase_kouhou@takeda.co.jp


International Media

Hannah Badri

Media_relations@takeda.com